...
inab-img

In8bio Inc, Common Stock

INAB

NMQ

$0.2685

-$0.02

(-6.94%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.41M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
257.14K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.07
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.22 L
$1.93 H
$0.2685

About In8bio Inc, Common Stock

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINABSectorS&P500
1-Week Return-16.38%-2.06%-0.55%
1-Month Return-19.03%-1.92%2.72%
3-Month Return-18.64%-10.4%7.66%
6-Month Return-73.15%-4.6%10.15%
1-Year Return-80.11%4.06%27.53%
3-Year Return-95.41%1.94%32.31%
5-Year Return-97.32%36.48%89.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue96.00K96.00K251.00K1.10M2.50M[{"date":"2019-12-31","value":3.84,"profit":true},{"date":"2020-12-31","value":3.84,"profit":true},{"date":"2021-12-31","value":10.04,"profit":true},{"date":"2022-12-31","value":44.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(96.00K)(96.00K)(251.00K)(1.10M)(2.50M)[{"date":"2019-12-31","value":-9600000,"profit":false},{"date":"2020-12-31","value":-9600000,"profit":false},{"date":"2021-12-31","value":-25100000,"profit":false},{"date":"2022-12-31","value":-110300000,"profit":false},{"date":"2023-12-31","value":-250100000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses5.07M8.56M14.65M28.52M30.34M[{"date":"2019-12-31","value":16.7,"profit":true},{"date":"2020-12-31","value":28.21,"profit":true},{"date":"2021-12-31","value":48.3,"profit":true},{"date":"2022-12-31","value":94.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(5.13M)(8.56M)(14.65M)(28.52M)(30.34M)[{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3033700000,"profit":false}]
Total Non-Operating Income/Expense(68.00K)----[{"date":"2019-12-31","value":-6800000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(5.13M)(8.56M)(14.65M)(28.52M)(30.01M)[{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}]
Income Taxes(68.00K)(118.30K)551.44K(1.10M)(32.84M)[{"date":"2019-12-31","value":-12.33,"profit":false},{"date":"2020-12-31","value":-21.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-200.02,"profit":false},{"date":"2023-12-31","value":-5954.93,"profit":false}]
Income After Taxes(5.07M)----[{"date":"2019-12-31","value":-506600000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(5.13M)(8.56M)(14.65M)(28.52M)(30.01M)[{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.13M)(8.56M)(14.65M)(27.42M)(30.01M)[{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2741800000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}]
EPS (Diluted)(1.71)(1.65)(1.83)(1.42)(1.01)[{"date":"2019-12-31","value":-170.99,"profit":false},{"date":"2020-12-31","value":-164.74,"profit":false},{"date":"2021-12-31","value":-183,"profit":false},{"date":"2022-12-31","value":-142,"profit":false},{"date":"2023-12-31","value":-101,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INAB
Cash Ratio 1.10
Current Ratio 1.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INAB
ROA (LTM) -77.64%
ROE (LTM) -180.45%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INAB
Debt Ratio Lower is generally better. Negative is bad. 0.46
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.54

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INAB
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.38
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is In8bio Inc share price today?

In8bio Inc (INAB) share price today is $0.2685

Can Indians buy In8bio Inc shares?

Yes, Indians can buy shares of In8bio Inc (INAB) on Vested. To buy In8bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of In8bio Inc be purchased?

Yes, you can purchase fractional shares of In8bio Inc (INAB) via the Vested app. You can start investing in In8bio Inc (INAB) with a minimum investment of $1.

How to invest in In8bio Inc shares from India?

You can invest in shares of In8bio Inc (INAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in INAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in In8bio Inc shares
What is In8bio Inc 52-week high and low stock price?

The 52-week high price of In8bio Inc (INAB) is $1.93. The 52-week low price of In8bio Inc (INAB) is $0.22.

What is In8bio Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of In8bio Inc (INAB) is

What is In8bio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of In8bio Inc (INAB) is 2.38

What is In8bio Inc dividend yield?

The dividend yield of In8bio Inc (INAB) is 0.00%

What is the Market Cap of In8bio Inc?

The market capitalization of In8bio Inc (INAB) is $20.41M

What is In8bio Inc’s stock symbol?

The stock symbol (or ticker) of In8bio Inc is INAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top